Table 5.
Treatment features of included articles
| Author | Duration of chemotherapy, (months) mean (SD) | Surgical treatment, n (%) | Follow-up evaluation (months), mean (SD) | Clinical improvement, n (%)a | Lost follow-up, n (%) |
|---|---|---|---|---|---|
| Prazuck et al. [33] | 8 (minimum) | - | - | 45/45 (100) | 0 (0) |
| Campos et al. [34] | - | 6 (22) | - | - | - |
| Richter et al. [35] | - | - | 3 (−) | - | - |
| Fam et al. [36] | 12 (minimum) | 5 (71) | 50 (−) | 5/5 (100) | 2 (29) |
| Puigdengolas et al. [37] | - | 5 (36) | - | - | - |
| Leibert et al. [38] | 12 (−) | 2 (29) | 12 (−) | 6/7 (86) | 0 (0) |
| Pertuiset et al. [25] | 14b | 25 (24) | 10b | 46/47 (98) | 56 (54) |
| Barrière et al. [10] | - | 3 (19) | - | 14/14 (100) | 2 (13) |
| Alothman et al. [39] | - | 32 (46) | 6 (minimum) | 32/33 (96) | - |
| Solagberu et al. [40] | 5 (6) | - | - | 4 (85) | |
| Garcia-Lechuz et al. [41] | 9 (−) | 9 (64) | 22 (−) | - | - |
| Rasit et al. [11] | 12 (−) | 30 (57) | 60 (−) | 50/53 (94) | 0 (0) |
| Rodriguez-Gómez et al. [42] | 11 (4) | 12 (32) | 7 (−) | 13/36 (36) | 1 (3) |
| Meddeb et al. [43] | 15 (−) | - | 16 (−) | 26/29 (90) | 0 (0) |
| Sakho et al. [44] | - | 39 (15) | 5 (−) | 118/148 (80) | 107 (42) |
| Dharmalingam et al. [45] | 9 (minimum) | 20 (61) | - | - | - |
| Colmenero et al. [12] | - | 55 (71) | 12 (−) | - | - |
| Schlesinger et al. [13] | 12 (−) | 10 (83) | - | 12/12 (100) | 0 (0) |
| López Cordoba et al. [46] | - | 29 (83) | - | - | - |
| Mulleman et al. [3] | - | - | - | - | - |
| Sharifi-Mood et al. [47] | - | - | - | - | - |
| Tasova et al. [48] | - | 34 (85) | - | 27/40 (68) | - |
| Kotil et al. [49] | - | - | - | 42/44 (95) | - |
| Park et al. [14] | 6–12 | 98 (72) | - | 94/116 (81) | - |
| Godlwana et al. [50] | - | - | - | - | - |
| Maeda et al. [15] | 12 (−) | 2 (9) | - | - | - |
| Kenyon et al. [51] | 12 (−) | - | 2 | 13/17 (77) | - |
| Polley et al. [5] | 9 (minimum) | 16 (100) | - | 15/16 (94) | 0 (0) |
| Owolabi et al. [21] | 8 (minimum) | - | 6 (minimum) | 20/67 (30) | 20 (23) |
| Su et al. [16] | 11 (4) | 30 (63) | 11 | 26/37 (70) | 11 (23) |
| Weng et al. [17] | 11b | 32 (84) | 11 | 24/34 (71) | 4 (11) |
| Benzagmout et al. [52] | 12 (−) | 7 (19) | 3 | 37/37 (100) | - |
| Kim et al. [53] | - | 40 (85) | - | - | - |
| Mwachaka et al. [54] | 9 (−) | 33 (26) | 6 | 91/129 (70) | 12 (9) |
| Alavi et al. [55] | - | 22 (32) | - | 53/69 (77) | 0 (0) |
| Lozano et al. [56] | 12 (−) | 3 (50) | 12 | 5/6 (83) | 0 (0) |
| Fedoul et al. [57] | - | 59 (72) | - | 78/82 (95) | - |
SD standard deviation
a Percentage over followed patients
b Data are expressed as median